Skip to main content Accessibility help
×
Home

Pharmacotherapy for obsessive—compulsive disorder

  • Naomi Fineberg and Angus Brown

Summary

We present a narrative review of evidence-based treatment for obsessive–compulsive disorder (OCD), covering first-line pharmacological treatment, augmentation strategies, approaches for treatment-refractory OCD and the management of OCD in special populations (children and adolescents, pregnant and breast-feeding women, and elderly people).

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Pharmacotherapy for obsessive—compulsive disorder
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Pharmacotherapy for obsessive—compulsive disorder
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Pharmacotherapy for obsessive—compulsive disorder
      Available formats
      ×

Copyright

Corresponding author

Professor Naomi Fineberg, Department of Psychiatry, Queen Elizabeth II Hospital, Howlands, Welwyn Garden City, Hertforshire AL7 4HQ. Email: naomi.fineberg@btinternet.com

Footnotes

Hide All

Declaration of Interest

N.F. has consulted for, received research support from, and/or received honoraria for lecturing at scientific meetings from: AstraZeneca, Bristol-Myers Squibb, Cephalon, European College of Neuropsychopharmacology, GlaxoSmithKline, the International College of Obsessive Compulsive Spectrum Disorders, Janssen, Jazz Pharmaceuticals, Lundbeck, Servier, the Wellcome Trust and Wyeth. A.B. worked for Roche Products and participated in research sponsored by Servier.

Footnotes

References

Hide All
Aboujaoude, E, Barry, JJ, Gamel, N (2009) Memantine augmentation in treatment-resistant obsessive–compulsive disorder: an open-label trial. Journal of Clinical Psychopharmacology 29: 51–5.
Ananth, J, Pecknold, JC, van den Steen, N et al (1981) Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Progress in Neuropsychopharmacology 5: 257–62.
Ansseau, M, Legros, JJ, Mormont, C et al (1987) Intranasal oxytocin in obsessive–compulsive disorder. Psychoneuroendocrinology 12: 231–6.
Baldwin, DS, Anderson, IM, Nutt, DJ et al (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 19: 567–96.
Bejerot, S, Bodlund, O (1998) Response to high doses of citalopram in treatment-resistant obsessive–compulsive disorder. Acta Psychiatrica Scandinavica 98: 423–4.
Bergeron, R, Ravindran, AV, Chaput, Y et al (2002) Sertraline and fluoxetine treatment of obsessive–compulsive disorder: results of a double-blind, 6-month treatment study. Journal of Clinical Psychopharmacology 22: 148–54.
Bloch, MH, Landeros-Weisenberger, A, Kelmendi, B et al (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive–compulsive disorder. Molecular Psychiatry 11: 622–32.
Blom, RM, Figee, M, Vulink, N et al (2011) Update on repetitive transcranial magnetic stimulation in obsessive compulsive disorder: different targets. Current Psychiatry Reports 13: 289–94.
Bogetto, F, Albert, U, Maina, G (2002) Sertraline treatment of obsessive–compulsive disorder: efficacy and tolerability of a rapid titration regimen. European Neuropsychopharmacology 12: 181–6.
Byerly, MJ, Goodman, WK, Christensen, R (1996) High doses of sertraline for treatment-resistant obsessive–compulsive disorder. American Journal of Psychiatry 153: 1232–3.
Bystritsky, A, Ackerman, DL, Rosen, RM et al (2004) Augmentation of serotonin reuptake inhibitors in refractory obsessive–compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. Journal of Clinical Psychiatry 65: 565–8.
Carey, PD, Vythilingum, B, Seedat, S et al (2005) Quetiapine augmentation of SRIs in treatment refractory obsessive–compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry 5: 5.
Clomipramine Collaborative Study Group (1991) Clomipramine in the treatment of patients with obsessive–compulsive disorder. Archives of General Psychiatry 48: 730–8.
Connor, KM, Payne, VM, Gadde, KM et al (2005) The use of aripiprazole in obsessive–compulsive disorder: preliminary observations in 8 patients. Journal of Clinical Psychiatry 66: 4951.
Coric, V, Taskiran, S, Pittenger, C et al (2005) Riluzole augmentation in treatment-resistant obsessive–compulsive disorder: an open-label trial. Biological Psychiatry 58: 424–8.
Cottraux, J, Mollard, E, Bouvard, M et al (1990) A controlled study of fluvoxamine and exposure in obsessive–compulsive disorder. International Clinical Psychopharmacology 5: 1730.
Dale, RC, Heyman, I, Giovannoni, G et al (2005) Incidence of anti-brain antibodies in children with obsessive–compulsive disorder. British Journal of Psychiatry 187: 314–9.
de Koning, PP, Figee, M, van den Munckhof, P et al (2011) Current status of deep brain stimulation for obsessive–compulsive disorder: a clinical review of different targets. Current Psychiatry Reports 13: 274–82.
den Boer, JA, Westenberg, HG (1992) Oxytocin in obsessive compulsive disorder. Peptides 13: 1083–5.
Denys, D, van der Wee, N, van Megen, HJ et al (2003) A double blind comparison of venlafaxine and paroxetine in obsessive–compulsive disorder. Journal of Clinical Psychopharmacology 23: 568–75.
Denys, D, van Megen, HJ, van der Wee, N et al (2004a) A double-blind switch study of paroxetine and venlafaxine in obsessive–compulsive disorder. Journal of Clinical Psychiatry 65: 3743.
Denys, D, De Geus, F, van Megen, HJ et al (2004b) A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive–compulsive disorder refractory to serotonin reuptake inhibitors. Journal of Clinical Psychiatry 65: 1040–8.
Denys, D, Fineberg, N, Carey, PD et al (2007) Quetiapine addition in obsessive–compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biological Psychiatry 61: 412–4.
De Veaugh-Geiss, J, Moroz, G, Biederman, J et al (1992) Clomipramine hydrochloride in childhood and adolescent obsessive compulsive disorder: a multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry 31: 45–9.
Diniz, JB, Fossaluza, V, de Braganga Pereira, CA et al (2011) Clomipramine and quetiapine augmentation for obsessive compulsive disorder compared with sustained fluoxetine treatment. Society of Biological Psychiatry 66th Annual Meeting 2011 (http://posters.f1000.com/Image?posterID=1197&type=poster).
Emslie, G, Judge, R (2000) Tricyclic antidepressants and selective serotonin reuptake inhibitors: use during pregnancy, in children/adolescents and in the elderly. Acta Psychiatrica Scandinavica Supplementum 403: 2634.
Erzegovesi, S, Guglielmo, E, Siliprandi, F et al (2005) Low-dose risperidone augmentation of fluvoxamine treatment in obsessive–compulsive disorder: a double-blind, placebo-controlled study. European Neuropsychopharmacology 15: 6974.
Feusner, JD, Kerwin, L, Saxena, S et al (2009) Differential efficacy of memantine for obsessive–compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacology Bulletin 42: 8193.
Fineberg, N (1999) Evidence-based pharmacotherapy for obsessive–compulsive disorder. Advances in Psychiatric Treatment 5: 357–65.
Fineberg, N, Heyman, I, Jenkins, R et al (2004) Does childhood and adult obsessive compulsive disorder (OCD) respond the same way to treatment with serotonin reuptake inhibitors (SRIs)? European Neuropsychopharmacology 14 (suppl 3): S191.
Fineberg, NA, Gale, TM (2005a) Evidence-based pharmacotherapy of obsessive–compulsive disorder. International Journal of Neuropsychopharmacology 8: 107–29.
Fineberg, NA, Sivakumaran, T, Roberts, A et al (2005b) Adding quetiapine to SRI in treatment-resistant obsessive–compulsive disorder: a randomized controlled treatment study. International Clinical Psychopharmacology 20: 223–6.
Fineberg, NA, Gale, TM, Sivakumaran, T (2006a) A review of antipsychotics in the treatment of obsessive compulsive disorder. Journal of Psychopharmacology 20: 97103.
Fineberg, NA, Nigam, N, Sivakumaran, T (2006b) Pharmacological strategies for treatment-resistant obsessive compulsive disorder. Psychiatric Annals 36: 464–74.
Fineberg, NA, Stein, DJ, Premkumar, P et al (2006c) Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive–compulsive disorder: a meta-analysis of randomized controlled treatment trials. International Clinical Psychopharmacology 21: 337–43.
Fineberg, NA, Tonnoire, B, Lemming, O et al (2007a) Escitalopram prevents relapse of obsessive–compulsive disorder. European Neuropsychopharmacology 17: 430–9.
Fineberg, NA, Pampaloni, I, Pallanti, S et al (2007b) Sustained response versus relapse: the pharmacotherapeutic goal for obsessive compulsive disorder. International Clinical Psychopharmacology 22: 313–22.
Flament, MF, Rapoport, JL, Berg, CJ et al (1985) Clomipramine treatment of childhood obsessive–compulsive disorder: a double-blind controlled study. Archives of General Psychiatry 42: 977–83.
Geller, DA, Biederman, J, Stewart, SE et al (2003a) Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive–compulsive disorder. American Journal of Psychiatry 160: 1919–28.
Geller, DA, Biederman, J, Stewart, SE et al (2003b) Impact of comorbidity on treatment response to paroxetine in pediatric obsessive–compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? Journal of Child and Adolescent Psychopharmacology 13 (suppl 1): S1929.
Geller, DA, Wagner, KD, Emslie, G et al (2004) Paroxetine treatment in children and adolescents with obsessive–compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 43: 1387–96.
Goodman, WK, Price, LH, Rasmussen, SA et al (1989) The Yale-Brown Obsessive Compulsive Scale: II. Validity. Archives of General Psychiatry 46: 1012–6.
Goodman, WK, Price, LH, Delgado, PL et al (1990) Specificity of serotonin reuptake inhibitors in the treatment of obsessive–compulsive disorder: comparison of fluvoxamine and desipramine. Archives of General Psychiatry 47: 577–85.
Goodman, WK, Kozak, MJ, Liebowitz, M et al (1996) Treatment of obsessive–compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. International Clinical Psychopharmacology 11: 21–9.
Grant, P, Lougee, L, Hirschtritt, M et al (2007) An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive–compulsive disorder. Journal of Child and Adolescent Psychopharmacology 17: 761–7.
Grant, P, Song, JY, Swedo, SE (2010) Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive–compulsive disorder. Journal of Child and Adolescent Psychopharmacology 20: 309–15.
Greenberg, WM, Benedict, MM, Doerfer, J et al (2009) Adjunctive glycine in the treatment of obsessive–compulsive disorder in adults. Journal of Psychiatric Research 43: 664–70.
Greist, JH, Jefferson, JW, Rosenfeld, R et al (1990) Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients. Journal of Clinical Psychiatry 51: 292–7.
Greist, JH, Jefferson, JW, Kobak, KA et al (1995a) A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive–compulsive disorder. International Clinical Psychopharmacology 10: 5765.
Greist, J, Chouinard, G, DuBoff, E et al (1995b) Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive–compulsive disorder. Archives of General Psychiatry 52: 289–95.
Guy, W (1976) ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education, and Welfare.
Hohagen, F, Winkelmann, G, Rasche-Rüchle, H et al (1998) Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: results of a multicentre study. British Journal of Psychiatry 173 (suppl 35): 71–8.
Hollander, E, Koran, LM, Goodman, WK et al (2003a) A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive–compulsive disorder. Journal of Clinical Psychiatry 64: 640–7.
Hollander, E, Allen, A, Steiner, M et al (2003b) Acute and long-term treatment and prevention of relapse of obsessive–compulsive disorder with paroxetine. Journal of Clinical Psychiatry 64: 1113–21.
Insel, TR, Murphy, DL, Cohen, RM et al (1983) obsessive–compulsive disorder: a double-blind trial of clomipramine and clorgyline. Archives of General Psychiatry 40: 605–12.
Insel, TR, Mueller, EA, Gillin, JC et al (1985) Tricyclic response in obsessive compulsive disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 9: 2531.
Jenike, MA, Baer, L, Minichiello, WE et al (1997) Placebo-controlled trial of fluoxetine and phenelzine for obsessive–compulsive disorder. American Journal of Psychiatry 154: 1261–4.
Jung, HH, Kim, CH, Chang, JH et al (2006) Bilateral anterior cingulotomy for refractory obsessive–compulsive disorder: long-term follow-up results. Stereotactic and Functional Neurosurgery 84: 184–9.
Kaplan, A, Hollander, E (2003) A review of pharmacologic treatments for obsessive–compulsive disorder. Psychiatric Services 54: 1111–8.
Koran, LM, Sallee, FR, Pallanti, S (1997) Rapid benefit of intravenous pulse loading of clomipramine in obsessive–compulsive disorder. American Journal of Psychiatry 154: 396401.
Koran, LM, Hackett, E, Rubin, A et al (2002) Efficacy of sertraline in the long-term treatment of obsessive–compulsive disorder. American Journal of Psychiatry 159: 8895.
Koran, LM, Aboujaoude, E, Bullock, KD et al (2005) Double-blind treatment with oral morphine in treatment-resistant obsessive–compulsive disorder. Journal of Clinical Psychiatry 66: 353–9.
Krack, P, Hariz, MI, Baunez, C et al (2010) Deep brain stimulation: from neurology to psychiatry? Trends in Neuroscience 33: 474–84.
Kronig, MH, Apter, J, Asnis, G et al (1999) Placebo-controlled, multicenter study of sertraline treatment for obsessive–compulsive disorder. Journal of Clinical Psychopharmacology 19: 172–6.
Kushner, MG, Kim, SW, Donahue, C et al (2007) D-cycloserine augmented exposure therapy for obsessive–compulsive disorder. Biological Psychiatry 62: 835–8.
Leonard, HL, Swedo, SE, Rapoport, JL et al (1989) Treatment of obsessive–compulsive disorder with clomipramine and desipramine in children and adolescents: a double-blind crossover comparison. Archives of General Psychiatry 46: 1088–92.
Levine, J (1997) Controlled trials of inositol in psychiatry. European Neuropsychopharmacology 7: 147–55.
Liebowitz, MR, Turner, SM, Piacentini, J et al (2002) Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 41: 1431–8.
March, JS, Frances, A, Kahn, DA et al (1997) The Expert Consensus Guideline Series: treatment of obsessive compulsive disorder. Journal of Clinical Psychiatry 58 (suppl): 172.
March, JS, Klee, BJ, Kremer, CM (2006) Treatment benefit and the risk of suicidality in multicenter, randomized, controlled trials of sertraline in children and adolescents. Journal of Child and Adolescent Psychopharmacology 16: 91102.
Marks, IM, Stern, RS, Mawson, D et al (1980) Clomipramine and exposure for obsessive–compulsive rituals: i. British Journal of Psychiatry 136: 125.
Matthews, K, Eljamel, MS (2003) Status of neurosurgery for mental disorder in Scotland: selective literature review and overview of current clinical activity. British Journal of Psychiatry 182: 404–11.
Mavissakalian, M, Turner, SM, Michelson, L et al (1985) Tricyclic antidepressants in obsessive–compulsive disorder: antiobsessional or anti-depressant agents? II. American Journal of Psychiatry 142: 572–6.
McDougle, CJ, Goodman, WK, Price, LH et al (1990) Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder. American Journal of Psychiatry 147: 652–4.
McDougle, CJ, Goodman, WK, Leckman, JF et al (1994) Haloperidol addition in fluvoxamine-refractory obsessive–compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Archives of General Psychiatry 51: 302–8.
McDougle, CJ, Barr, LC, Goodman, WK et al (1995) Lack of efficacy of clozapine monotherapy in refractory obsessive–compulsive disorder. American Journal of Psychiatry 152: 1812–4.
McDougle, CJ, Barr, LC, Goodman, WK et al (1999) Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 24: 124.
McDougle, CJ, Epperson, CN, Pelton, GH et al (2000) A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive–compulsive disorder. Archives of General Psychiatry 57: 794801.
McDougle, CJ, Walsh, KH (2001) Treatment of refractory OCD. In Obsessive Compulsive Disorder: A Practical Guide (eds Fineberg, NA, Marazitti, D, Stein, D) 135–52. Martin Dunitz.
Mens, WB, Laczi, F, Tonnaer, JA et al (1983) Vasopressin and oxytocin content in cerebrospinal fluid and in various brain areas after administration of histamine and pentylenetetrazol. Pharmacology, Biochemistry & Behavior 19: 587–91.
Montgomery, SA (1980) Clomipramine in obsessional neurosis: a placebo-controlled trial. Pharmacological Medicine 1: 189–92.
Montgomery, SA, McIntyre, A, Osterheider, M et al (1993) A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive–compulsive disorder. European Neuropsychopharmacology 3: 143–52.
Montgomery, SA, Kasper, S, Stein, DJ et al (2001) Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive–compulsive disorder. International Clinical Psychopharmacology 16: 7586.
National Collaborating Centre for Mental Health (2006) Obsessive–Compulsive Disorder: Core Interventions in the Treatment of Obsessive–Compulsive Disorder and Body Dysmorphic Disorder (Clinical Guideline CG31). National Institute for Health and Clinical Excellence.
National Collaborating Centre for Mental Health (2007) Antenatal and Postnatal Mental Health (Clinical Guideline CG45). National Institute for Health and Clinical Excellence.
Ninan, PT, Koran, LM, Kiev, A et al (2006) High-dose sertraline strategy for nonresponders to acute treatment for obsessive–compulsive disorder: a multicenter double-blind trial. Journal of Clinical Psychiatry 67: 1522.
Pallanti, S, Quercioli, L, Bruscoli, M (2004) Response acceleration with mirtazapine augmentation of citalopram in obsessive–compulsive disorder patients without comorbid depression: a pilot study. Journal of Clinical Psychiatry 65: 1394–9.
Pediatric OCD Treatment Study (POTS) Team (2004) Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive–compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 292: 1969–76.
Pittenger, C, Krystal, JH, Coric, V (2006) Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive–compulsive disorder NeuroRx. Journal of the American Society for Experimental NeuroTherapeutics 3: 6981.
Pittenger, C, Coric, V, Banasr, M et al (2008) Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 22: 761–86.
Ravindran, LN, Jung, SM, Ravindran, AV (2010) Intravenous anti-obsessive agents: a review. Journal of Psychopharmacology 24: 287–96.
Richter, MA, Summerfeldt, LJ, Antony, MM et al (2003) obsessive–compulsive spectrum conditions in obsessive–compulsive disorder and other anxiety disorders. Depression and Anxiety 18: 118–27.
Riddle, MA, Scahill, L, King, RA et al (1992) Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive–compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry 31: 1062–9.
Riddle, MA, Reeve, EA, Yaryura-Tobias, JA et al (2001) Fluvoxamine for children and adolescents with obsessive–compulsive disorder: a randomized, controlled, multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry 40: 222–9.
Romano, S, Goodman, W, Tamura, R et al (2001) Long-term treatment of obsessive–compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. Journal of Clinical Psychopharmacology 21: 4652.
Rosenberg, DR, MacMaster, FP, Keshavan, MS et al (2000) Decrease in caudate glutamatergic concentrations in pediatric obsessive–compulsive disorder patients taking paroxetine. Journal of the American Academy of Child and Adolescent Psychiatry 39: 1096–103.
Rück, C, Andréewitch, S, Flyckt, K et al (2003) Capsulotomy for refractory anxiety disorders: long-term follow-up of 26 patients. American Journal of Psychiatry 160: 513–21.
Rufer, M, Hand, I, Alsleben, H et al (2005) Long-term course and outcome of obsessive–compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial. European Archives of Psychiatry and Clinical Neuroscience 255: 121–8.
Sánchez, C, Bøgesø, KP, Ebert, B et al (2004) Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 174: 163–76.
Shapira, NA, Ward, HE, Mandoki, M et al (2004) A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive–compulsive disorder. Biological Psychiatry 55: 553–5.
Simpson, HB, Huppert, JD, Petkova, E et al (2006) Response versus remission in obsessive–compulsive disorder. Journal of Clinical Psychiatry 67: 269–76.
Simpson, HB, Foa, EB, Liebowitz, MR et al (2008) A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive–compulsive disorder. American Journal of Psychiatry 165: 621–30.
Skoog, G, Skoog, I (1999) A 40-year follow-up of patients with obsessive–compulsive disorder. Archives of General Psychiatry 56: 121–7.
Soltani, F, Sayyah, M, Feizy, F et al (2010) A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive–compulsive disorder. Human Psychopharmacology 25: 509–13.
Stein, DJ, Andersen, EW, Tonnoir, B et al (2007) Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Current Medical Research and Opinion 23: 701–11.
Stein, DJ, Carey, PD, Lochner, C et al (2008) Escitalopram in obsessive–compulsive disorder: response of symptom dimensions to pharmacotherapy. CNS Spectrums 13: 492–8.
Stewart, SE, Jenike, AE, Hezel, DM et al (2010) A single-blind case-control study of memantine in severe obsessive–compulsive disorder. Journal of Clinical Psychopharmacology 30: 34–9.
Storch, EA, Merlo, LJ, Bengtson, M et al (2007) D-cycloserine does not enhance exposure-response prevention therapy in obsessive–compulsive disorder. International Clinical Psychopharmacology 22: 230–7.
Storch, EA, Murphy, TK, Goodman, WK et al (2010) A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive–compulsive disorder. Biological Psychiatry 68: 1073–6.
Thoren, P, Asberg, M, Cronholm, B et al (1980) Clomipramine treatment of obsessive–compulsive disorder. I. A controlled clinical trial. Archives of General Psychiatry 37: 1281–5.
Tollefson, GD, Rampey, AH Jr, Potvin, JH et al (1994) A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive–compulsive disorder. Archives of General Psychiatry 51: 559–67.
Volavka, J, Neziroglu, F, Yaryura-Tobias, JA (1985) Clomipramine and imipramine in obsessive–compulsive disorder. Journal of Psychiatry Research 14: 8593.
Wilhelm, S, Buhlmann, U, Tolin, DF et al (2008) Augmentation of behavior therapy with D-cycloserine for obsessive–compulsive disorder. American Journal of Psychiatry 165: 335–41.
Yaryura-Tobias, JA, Neziroglu, F (1975) The action of chlorimipramine in obsessive–compulsive neurosis: a pilot study. Current Therapeutic Research, Clinical and Experimental 17: 111–6.
Zohar, J, Judge, R (1996) Paroxetine versus clomipramine in the treatment of obsessive–compulsive disorder. British Journal of Psychiatry 169: 468–74.

Related content

Powered by UNSILO

Pharmacotherapy for obsessive—compulsive disorder

  • Naomi Fineberg and Angus Brown

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Pharmacotherapy for obsessive—compulsive disorder

  • Naomi Fineberg and Angus Brown
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *